Clinical Immunology Communications最新文献_第6页

Increased percentage of HLA-DR T cells in untreated juvenile dermatomyositis 未经治疗的幼年皮肌炎患者中 HLA-DR T 细胞比例增加

Clinical Immunology Communications Pub Date : 2024-06-01 Epub Date: 2024-02-22 DOI: 10.1016/j.clicom.2024.02.002

Amer Khojah , Madeline Schutt , Gabrielle Morgan , Ameera Bukhari , Nicolas Bensen , Aaruni Khanolkar , Lauren M. Pachman

{"title":"Increased percentage of HLA-DR T cells in untreated juvenile dermatomyositis","authors":"Amer Khojah , Madeline Schutt , Gabrielle Morgan , Ameera Bukhari , Nicolas Bensen , Aaruni Khanolkar , Lauren M. Pachman","doi":"10.1016/j.clicom.2024.02.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2024.02.002","url":null,"abstract":"<div><p>This study investigates HLA-DR expression on activated T cells and serum neopterin levels in Juvenile Dermatomyositis (JDM) children pre- and post-treatment. Sixty-nine JDM children (less than 18 years) were included. Elevated HLA-DR+ <em>T</em> cells (>7 %) were observed in 19 % of untreated cases. Post-treatment, mean HLA-DR+ <em>T</em> cells decreased from 5.1 to 2.9 (<em>P</em> < 0.001), and serum neopterin levels declined from 19.3 to 9.1 nmol/L (<em>P</em> < 0.0001). A positive correlation between serum neopterin and HLA-DR T cell percentage was observed (<em>r</em> = 0.39, <em>P</em> = 0.01). Intravenous steroid treatment exhibited a 47.4 % improvement in HLA-DR+ <em>T</em> cells and a 50.5 % reduction in serum neopterin levels, in contrast to 14.8 % and 34.1 % in the oral steroid group. In conclusion, treatment, particularly with IV steroids, significantly improved HLA-DR+ <em>T</em> cells percentage and neopterin levels. A correlation between HLA-DR+ <em>T</em> cells percentage and serum neopterin was noted in untreated JDM patients.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"5 ","pages":"Pages 20-25"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613424000052/pdfft?md5=c452f7a7248afcb618c034100a4de811&pid=1-s2.0-S2772613424000052-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139993378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

First reported use of immune checkpoint inhibitor for treatment of cancer in a patient with acquired hemophilia A 首次报道获得性血友病 A 患者使用免疫检查点抑制剂治疗癌症

Clinical Immunology Communications Pub Date : 2024-06-01 Epub Date: 2024-04-16 DOI: 10.1016/j.clicom.2024.04.001

Mariam A Mostafa , Sheref Elseidy , Reham Ali Metwally , Amir Mahmoud , Ali Abdelhay , Farhan S. Imran

{"title":"First reported use of immune checkpoint inhibitor for treatment of cancer in a patient with acquired hemophilia A","authors":"Mariam A Mostafa , Sheref Elseidy , Reham Ali Metwally , Amir Mahmoud , Ali Abdelhay , Farhan S. Imran","doi":"10.1016/j.clicom.2024.04.001","DOIUrl":"10.1016/j.clicom.2024.04.001","url":null,"abstract":"<div><p>Acquired hemophilia A is a rare but serious bleeding disorder that occurs because of neutralizing autoantibodies, also called inhibitors that target coagulation factor VIII (FVIII). Although it is a rare disorder, it has high morbidity and mortality with serious, sometimes life-threatening bleeding, often occurring. Immunotherapy with immune checkpoint inhibitors (ICI) is now a key pillar in treatment of malignancies. They have improved outcomes in malignancy but given their mechanism of action, which stimulates the immune response, autoimmune-associated adverse effects are a concern. Several case reports have identified a risk of AHA occurrence in patients treated with ICI. There are no case reports documenting the use or outcomes of ICI in patients with pre-existing AHA. Here we present the first ever case of a patient with AHA in complete remission treated successfully with ICI for lung cancer without relapse in AHA.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"5 ","pages":"Pages 41-44"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613424000076/pdfft?md5=7a969c587bdd6b21a30b1d5cc76f5f5e&pid=1-s2.0-S2772613424000076-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140762660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunopathogenesis of cutaneous T-cell lymphoma in skin of color patients part 1: Mycosis fungoides 有色皮肤患者皮肤t细胞淋巴瘤的免疫发病机制第一部分:蕈样真菌病

Clinical Immunology Communications Pub Date : 2023-12-15 Epub Date: 2023-07-20 DOI: 10.1016/j.clicom.2023.07.004

Sachi I. Desse , Nina C. Nwade , Akanksha Nagarkar , Nia E.R. James , Ryan Svoboda , Ginette A. Okoye , Angel S. Byrd , Jillian M. Richmond

引用次数: 0

Challenges in the diagnosis and management of SLE in India 印度SLE诊断和管理的挑战

Clinical Immunology Communications Pub Date : 2023-12-15 Epub Date: 2023-10-18 DOI: 10.1016/j.clicom.2023.10.001

Rudrarpan Chatterjee, Amita Aggarwal

引用次数: 0

Cross-protective immunity induced by omicron variant of SARS-CoV-2 SARS-CoV-2组粒变异诱导的交叉保护性免疫

Clinical Immunology Communications Pub Date : 2023-12-15 Epub Date: 2023-07-20 DOI: 10.1016/j.clicom.2023.07.007

Selia Chowdhury , Md. Shahraj Chowdhury , Nurjahan Shipa Chowdhury , Samia Chowdhury , Shajeda Chowdhury

引用次数: 0

TBE-antibody titer study: Is a booster already necessary after 5 years? tbe抗体滴度研究:5年后是否需要加强?

Clinical Immunology Communications Pub Date : 2023-12-15 Epub Date: 2023-11-09 DOI: 10.1016/j.clicom.2023.11.001

Katharina Mahlfleisch, Susanne Pauschenwein, Thomas Pekar

引用次数: 0

Systemic lupus erythematosus in Latin America: Outcomes and therapeutic challenges 拉丁美洲的系统性红斑狼疮:结果和治疗挑战

Clinical Immunology Communications Pub Date : 2023-12-15 Epub Date: 2023-10-17 DOI: 10.1016/j.clicom.2023.10.002

Manuel F. Ugarte-Gil , Graciela S. Alarcón

引用次数: 0

Disseminated tuberculosis, CMV viraemia & haemophagocytic-lymphohistiocystosis syndrome in an adult patient with anti- IFNγ autoantibodies – case report and brief review 成人抗IFNγ自身抗体患者的弥散性结核、巨细胞病毒血症和噬血细胞淋巴组织囊积综合征——病例报告和简要回顾

Clinical Immunology Communications Pub Date : 2023-12-15 Epub Date: 2023-09-01 DOI: 10.1016/j.clicom.2023.08.001

G.I. Butel-Simoes , C. Kiss , K. Kong , L.B. Rosen , L.M. Hosking , S. Barnes , G.A. Jenkin , S. Megaloudis , B. Kumar , S.M. Holland , S. Ojaimi

引用次数: 0

Immune microenvironment and progress in immunotherapy of cholangiocarcinoma 胆管癌免疫微环境及免疫治疗进展

Clinical Immunology Communications Pub Date : 2023-12-15 Epub Date: 2023-11-29 DOI: 10.1016/j.clicom.2023.11.002

Xinyu Shao

引用次数: 0

Protective role of human beta-defensin-2 and cathelicidin in high risk close household contacts of pulmonary tuberculosis 人β-防御素-2和组织蛋白酶对肺结核高危家庭密切接触者的保护作用

Clinical Immunology Communications Pub Date : 2023-12-01 Epub Date: 2023-02-10 DOI: 10.1016/j.clicom.2023.02.006

Sudhasini Panda , Shah Faisal , Diravya M Seelan , Manisha Dagar , Lokesh Mandlecha , Vidushi Varshney , Mridul Sharma , Kalpana Luthra , Neeraj Kumar Gupta , Archana Singh

{"title":"Protective role of human beta-defensin-2 and cathelicidin in high risk close household contacts of pulmonary tuberculosis","authors":"Sudhasini Panda , Shah Faisal , Diravya M Seelan , Manisha Dagar , Lokesh Mandlecha , Vidushi Varshney , Mridul Sharma , Kalpana Luthra , Neeraj Kumar Gupta , Archana Singh","doi":"10.1016/j.clicom.2023.02.006","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.02.006","url":null,"abstract":"<div><p>Host-defense peptides (HDPs) such as human beta-defensin-2 (hBD-2) and cathelicidin (LL37) are essential components of innate immune response against tuberculosis (TB) infection, which could also be assessed for diagnostic potential in spectrum of TB infection. We assessed mRNA and circulating levels of HDPs in pulmonary TB (PTB) patients and their household contacts (HHCs). hBD-2 and LL37 were found to be significantly higher in both PTB and HHCs suggestive of bacterial exposure which was further corroborated by higher levels of HDPs in mantoux positive HHCs (latent TB). Higher levels of HDPs in HHCs may suggest protective host response against infection as indicated by inverse relation of LL37 with disease severity in PTB. Both peptides demonstrated high levels of sensitivity and specificity, although hBD-2 proved to be a better HDP for distinguishing LTBI from active TB at a cutoff of 3904 pg/ml. However, follow-up studies are required to validate these findings.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"3 ","pages":"Pages 23-30"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49749275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0